In another win for mRNA, CureVac execs detail the new PhI readout of their vaccine data and why they’re so pumped about it
Pfizer may be out front in the race to develop the first new mRNA vaccine for Covid-19. But the clinical rivals to the pharma giant and BioNTech, which developed the vaccine, are still hell bent on jumping in fast enough to play a big role in defeating the current pandemic — and getting set up for whatever future outbreaks may bring us.
To that end, the CureVac team $CVAC is posting their Phase I data today — spelling out what researchers were able to determine among 251 patients after offering up the general top-line results a few days ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.